Keywords
autoantibodies
antigen arrays
immunoassay
Categories
How to Cite
Abstract
Autoimmune diseases are a diverse group of disorders characterized by immune disturbances that cause aberrant B cell and T cell reactivity to normal constituents of the host. Autoantibodies are commonly found in individuals with autoimmune diseases. A large number of autoantibodies are directed against intracellular or extracellular targets such as nucleic acids, structural proteins, enzymes, RNA binding proteins, receptors, cytokines, among others. The detection of these autoantibodies is key to the diagnosis and classification of patients with autoimmune diseases. In addition, some studies have shown that autoantibodies can appear years before the onset of an autoimmune disease; therefore, the detection of these antibodies would serve as early predictors of risk and would also help to choose a possible therapeutic intervention to prevent or delay the disease progression. Several methods, such as enzyme-linked immunosorbent assay (ELISA), immunofluorescence, fixed tissue or cell-based assays, are commonly used for the detection of autoantibodies. Although these technologies are limited in sensitivity, specificity, and sample throughput, therefore, new experimental techniques are continuously developed to discover novel autoantigens involved in autoimmune diseases. There are several limitations in the detection of autoantibodies, such as sensitivity and specificity, temporal variability in autoantibody levels, technical limitations, subjective interpretation, and lack of standards and quality controls in the tests. Autoantibody tests are only a diagnostic tool and must be used in combination with clinical evaluation for an accurate diagnosis. In this chapter, we will describe the technologies used in the detection of classic and new autoantibodies, exploring the assessment of clinical relevance, accuracy, validation, and possible regulatory requirements as an approved diagnostic test that could be promoted in routine clinical practice.
References
Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-395. doi:10.1111/joim.12395
Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity. Front Immunol. 2021;12:548469. doi:10.3389/fimmu.2021.548469
Burbelo PD, O’Hanlon TP. New autoantibody detection technologies yield novel insights into autoimmune disease. Curr Opin Rheumatol. 2014;26(6):717-723. doi:10.1097/BOR.0000000000000107
Carlton LH, McGregor R, Moreland NJ. Human antibody profiling technologies for autoimmune disease. Immunol Res. Published online January 2023:1-12. doi:10.1007/s12026-023-09362-8
Xiao ZX, Miller JS, Zheng SG. An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev. 2021;20(2):102743. doi:10.1016/j.autrev.2020.102743
Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387-94. doi:10.1016/j.autrev.2009.11.010
Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316-1322. doi:10.1136/annrheumdis-2013-204627
Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. Published online May 2023:1-16. doi:10.1038/s41581-023-00720-1
Yu X, Wax J, Riemekasten G, Petersen F. Functional autoantibodies: Definition, mechanisms, origin and contributions to autoimmune and non-autoimmune disorders. Autoimmun Rev. Published online 2023:103386. doi:https://doi.org/10.1016/j.autrev.2023.103386
Pacheco Y, Monsalve DM, Acosta-Ampudia Y, Rojas C, Anaya JM, Ramírez-Santana C. Antinuclear autoantibodies: discordance among four different assays. Ann Rheum Dis. 2020;79(1):e6. doi:10.1136/annrheumdis-2018-214693
Tozzoli R, Antico A, Porcelli B, Bassetti D. Automation in indirect immunofluorescence testing: a new step in the evolution of the autoimmunology laboratory. Auto- Immun highlights. 2012;3(2):59-65. doi:10.1007/s13317-012-0035-2
Chan EKL, Damoiseaux J, de Melo Cruvinel W, et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus. 2016;25(8):797-804. doi:10.1177/0961203316640920
Irure-Ventura J, López-Hoyos M. The Past, Present, and Future in Antinuclear Antibodies (ANA). Diagnostics (Basel, Switzerland). 2022;12(3). doi:10.3390/diagnostics12030647
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. doi:10.1136/annrheumdis-2018-214819
Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014;2014:315179. doi:10.1155/2014/315179
Mahler M, Ngo JT, Schulte-Pelkum J, Luettich T, Fritzler MJ. Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther. 2008;10(6):R131. doi:10.1186/ar2548
Keech CL, McCluskey J, Gordon TP. Transfection and overexpression of the human 60-kDa Ro/SS-A autoantigen in HEp-2 cells. Clin Immunol Immunopathol. 1994;73(1):146-151. doi:10.1006/clin.1994.1181
Malyavantham K, Suresh L. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Auto- Immun highlights. 2017;8(1):3. doi:10.1007/s13317-017-0091-8
Bertin D, Jourde-Chiche N, Bongrand P, Bardin N. Original approach for automated quantification of antinuclear autoantibodies by indirect immunofluorescence. Clin Dev Immunol. 2013;2013:182172. doi:10.1155/2013/182172
Roggenbuck D, Hiemann R, Schierack P, Reinhold D, Conrad K. Digital immunofluorescence enables automated detection of antinuclear antibody endpoint titers avoiding serial dilution. Clin Chem Lab Med. 2014;52(2):e9-11. doi:10.1515/cclm-2013-0543
Fenger M, Wiik A, Høier-Madsen M, et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis. Clin Chem. 2004;50(11):2141-2147. doi:10.1373/clinchem.2004.038422
Copple SS, Sawitzke AD, Wilson AM, Tebo AE, Hill HR. Enzyme-linked immunosorbent assay screening then indirect immunofluorescence confirmation of antinuclear antibodies: a statistical analysis. Am J Clin Pathol. 2011;135(5):678-684. doi:10.1309/AJCP6R8EELGODAYW
Deutschmann C, Roggenbuck D, Schierack P, Rödiger S. Autoantibody testing by enzyme-linked immunosorbent assay-a case in which the solid phase decides on success and failure. Heliyon. 2020;6(1):e03270. doi:10.1016/j.heliyon.2020.e03270
Lee SA, Kahng J, Kim Y, et al. Comparative study of immunofluorescent antinuclear antibody test and line immunoassay detecting 15 specific autoantibodies in patients with systemic rheumatic disease. J Clin Lab Anal. 2012;26(4):307-314. doi:10.1002/jcla.21522
To F, Ventín-Rodríguez C, Elkhalifa S, Lilleker JB, Chinoy H. Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. BMC Rheumatol. 2020;4:28. doi:10.1186/s41927-020-00132-9
Mahler M, Bentow C, Serra J, Fritzler MJ. Detection of autoantibodies using chemiluminescence technologies. Immunopharmacol Immunotoxicol. 2016;38(1):14-20. doi:10.3109/08923973.2015.1077461
Ghillani P, Rouquette AM, Desgruelles C, et al. Evaluation of the LIAISON ANA screen assay for antinuclear antibody testing in autoimmune diseases. Ann N Y Acad Sci. 2007;1109:407-413. doi:10.1196/annals.1398.046
Mahler M, Gascon C, Patel S, et al. Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther. 2013;15(2):R50. doi:10.1186/ar4210
Musset L, Miyara M, Benveniste O, et al. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies. J Immunol Res. 2014;2014:405956. doi:10.1155/2014/405956
Damoiseaux J, van Beers J. Autoantibodies to dsDNA in the diagnosis, classification and follow-up of patients with systemic lupus erythematosus. J Transl Autoimmun. 2023;6:100191. doi:10.1016/j.jtauto.2023.100191
Rönnelid J, Turesson C, Kastbom A. Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives. Front Immunol. 2021;12:685312. doi:10.3389/fimmu.2021.685312
Cinquanta L, Fontana DE, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Auto- Immun highlights. 2017;8(1):9. doi:10.1007/s13317-017-0097-2
Ricken G, Schwaiger C, De Simoni D, et al. Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis. Front Neurol. 2018;9:841. doi:10.3389/fneur.2018.00841
Gao F, Zhang Y, Lv J, et al. How to improve the sensitivity and specificity of cell-based assays in detecting autoantibodies in neuroimmune diseases. Ann Transl Med. 2023;11(7):281. doi:10.21037/atm-21-3072
Rodriguez Cruz PM, Huda S, López-Ruiz P, Vincent A. Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Exp Neurol. 2015;270:66-71. doi:https://doi.org/10.1016/j.expneurol.2015.01.011
Molina RD, Conzatti LP, da Silva APB, et al. Detection of autoantibodies in central nervous system inflammatory disorders: Clinical application of cell-based assays. Mult Scler Relat Disord. 2020;38:101858. doi:10.1016/j.msard.2019.101858
Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol. 2007;125(2):120-126. doi:10.1016/j.clim.2007.08.005
Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes. 1997;46(11):1701-1710. doi:10.2337/diab.46.11.1701
Valdez SN, Iacono RF, Villalba A, Cardoso Landaburu A, Ermácora MR, Poskus E. A radioligand-binding assay for detecting antibodies specific for proinsulin and insulin using 35S-proinsulin. J Immunol Methods. 2003;279(1):173-181. doi:https://doi.org/10.1016/S0022-1759(03)00197-2
Wenzlau JM, Liu Y, Yu L, et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes. 2008;57(10):2693-2697. doi:10.2337/db08-0522
Shum AK, Alimohammadi M, Tan CL, et al. BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease. Sci Transl Med. 2013;5(206):206ra139. doi:10.1126/scitranslmed.3006998
Burbelo PD, Lebovitz EE, Notkins AL. Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl Res. 2015;165(2):325-335. doi:10.1016/j.trsl.2014.08.006
Yamakawa M, Mukaino A, Kimura A, et al. Antibodies to the α3 subunit of the ganglionic-type nicotinic acetylcholine receptors in patients with autoimmune encephalitis. J Neuroimmunol. 2020;349:577399. doi:10.1016/j.jneuroim.2020.577399
Hoang TTT, Ichinose K, Morimoto S, Furukawa K, Le LHT, Kawakami A. Measurement of anti-suprabasin antibodies, multiple cytokines and chemokines as potential predictive biomarkers for neuropsychiatric systemic lupus erythematosus. Clin Immunol. 2022;237:108980. doi:10.1016/j.clim.2022.108980
Mukaino A, Nakane S, Higuchi O, et al. Insights from the ganglionic acetylcholine receptor autoantibodies in patients with Sjögren’s syndrome. Mod Rheumatol. 2016;26(5):708-715. doi:10.3109/14397595.2016.1147404
Maeda Y, Nakane S, Higuchi O, et al. Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases including primary biliary cirrhosis. Mod Rheumatol. 2017;27(4):664-668. doi:10.1080/14397595.2016.1226469
Burbelo PD, Gordon SM, Waldman M, et al. Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS One. 2019;14(3):e0214202. doi:10.1371/journal.pone.0214202
Ling Y, Jiang P, Li N, Yan Q, Wang X. A luciferase immunoprecipitation assay for the detection of proinsulin/insulin autoantibodies. Clin Biochem. 2018;54:51-55. doi:https://doi.org/10.1016/j.clinbiochem.2018.02.011
Burbelo PD, Browne SK, Sampaio EP, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood. 2010;116(23):4848-4858. doi:10.1182/blood-2010-05-286161
Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2001;2(2):RESEARCH0004. doi:10.1186/gb-2001-2-2-research0004
Ayoglu B, Häggmark A, Neiman M, et al. Systematic antibody and antigen-based proteomic profiling with microarrays. Expert Rev Mol Diagn. 2011;11(2):219-234. doi:10.1586/erm.10.110
Ayoglu B, Häggmark A, Khademi M, et al. Autoantibody Profiling in Multiple Sclerosis Using Arrays of Human Protein Fragments*. Mol Cell Proteomics. 2013;12(9):2657-2672. doi:https://doi.org/10.1074/mcp.M112.026757
Zhu H, Luo H, Yan M, Zuo X, Li QZ. Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus. Genomics Proteomics Bioinformatics. 2015;13(4):210-218. doi:https://doi.org/10.1016/j.gpb.2015.09.001
Sokolove J, Lindstrom TM, Robinson WH. Development and deployment of antigen arrays for investigation of B-cell fine specificity in autoimmune disease. Front Biosci (Elite Ed). 2012;4(1):320-330. doi:10.2741/379
Petersson L, Dexlin-Mellby L, Bengtsson AA, Sturfelt G, Borrebaeck CAK, Wingren C. Multiplexing of miniaturized planar antibody arrays for serum protein profiling--a biomarker discovery in SLE nephritis. Lab Chip. 2014;14(11):1931-1942. doi:10.1039/c3lc51420j
Ayoglu B, Schwenk JM, Nilsson P. Antigen arrays for profiling autoantibody repertoires. Bioanalysis. 2016;8(10):1105-1126. doi:10.4155/bio.16.31
Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman Jr. JR. Advanced multiplexed analysis with the FlowMetrixTM system. Clin Chem. 1997;43(9):1749-1756. doi:10.1093/clinchem/43.9.1749
Budde P, Zucht HD, Vordenbäumen S, et al. Multiparametric detection of autoantibodies in systemic lupus erythematosus. Lupus. 2016;25(8):812-822. doi:10.1177/0961203316641770
Price J V, Haddon DJ, Kemmer D, et al. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J Clin Invest. 2013;123(12):5135-5145. doi:10.1172/JCI70231
Olsen NJ, Choi MY, Fritzler MJ. Emerging technologies in autoantibody testing for rheumatic diseases. Arthritis Res Ther. 2017;19(1):172. doi:10.1186/s13075-017-1380-3
Albon S, Bunn C, Swana G, Karim Y. Performance of a multiplex assay compared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis. J Immunol Methods. 2011;365(1-2):126-131. doi:10.1016/j.jim.2010.12.010
Kaul R, Johnson K, Scholz H, Marr G. Performance of the BioPlex 2200 Autoimmune Vasculitis kit. Autoimmun Rev. 2009;8(3):224-227. doi:10.1016/j.autrev.2008.07.033
Sowa M, Großmann K, Scholz J, et al. The CytoBead assay – a novel approach of multiparametric autoantibody analysis in the diagnostics of systemic autoimmune diseases. 2015;38(s1). doi:doi:10.1515/labmed-2015-0036
Sowa M, Grossmann K, Knütter I, et al. Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. PLoS One. 2014;9(9):e107743. doi:10.1371/journal.pone.0107743
Abdukhakimova D, Dossybayeva K, Grechka A, et al. Reliability of the Multiplex CytoBead CeliAK Immunoassay to Assess Anti-tTG IgA for Celiac Disease Screening. Front Med. 2021;8:731067. doi:10.3389/fmed.2021.731067
Wang EY, Dai Y, Rosen CE, et al. High-throughput identification of autoantibodies that target the human exoproteome. Cell Reports Methods. 2022;2(2):100172. doi:https://doi.org/10.1016/j.crmeth.2022.100172
Chan EKL, Fritzler MJ, Wiik A, et al. AutoAbSC.Org -- Autoantibody Standardization Committee in 2006. Autoimmun Rev. 2007;6(8):577-580. doi:10.1016/j.autrev.2007.05.001
James K, Carpenter AB, Cook L, Marchand R, Nakamura RM. Development of the antinuclear and anticytoplasmic antibody consensus panel by the Association of Medical Laboratory Immunologists. Clin Diagn Lab Immunol. 2000;7(3):436-443. doi:10.1128/CDLI.7.3.436-443.2000
Chin A, Choi MY, Fritzler MJ. Gaps and Trends in Autoantibody Testing. J Appl Lab Med. 2022;7(1):362-366. doi:10.1093/jalm/jfab153
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Y. Acosta-Ampudia, D. Monsalve, Carolina Ramirez-Santana (Author)